Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Rivaroxaban is an oral, direct Factor Xa inhibitor that targets free and clot-bound Factor Xa and Factor Xa in the prothrombinase complex. It is absorbed rapidly, with maximum plasma concentrations being reached 2–4 h after tablet intake. Oral bioavailability is high (80–100 %) for the 10 mg tablet...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer International Publishing
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889701/ |